Tivic reports FY2025 net loss $8.8M-$9.1M; pivots to immunotherapy with Entolimod

Valion Bio, Inc.

Operating expenses $7.9M in 2025 vs $4.5M in 2024; net loss before disc. ops $7.9M-$8.1M.
Cash $12.6M at Dec 31, 2025 vs $2.0M at prior year-end; working capital $12.4M.
Acquired global rights to Entolimod for acute radiation syndrome; discontinued ClearUP/VNS.
CEO Michael K. Handley appointed March 2026, succeeding Jennifer Ernst.
Engaged with BARDA, DTRA, NIH, NIAID for potential Entolimod funding or procurement.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Valion Bio, Inc. reported year ended December 31, 2025 results: net income expected to be in the range of $8.8 million to $9.1 million.

Period: year ended December 31, 2025
Net income: expected to be in the range of $8.8 million to $9.1 million
Result: reported results

Exact text from the filing

Net loss for the year ended December 31, 2025 is expected to be in the range of $8.8 million to $9.1 million, compared with $5.7 million for the year ended December 31, 2024.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Valion Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-26-009789

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.